Vertriebs- Und Verwaltungskosten Veränderung Datum
Alnylam Pharmaceuticals USD 262.59M 60.72M 2025-09
BioCryst Pharmaceuticals USD 80.47M 15.39M 2024-12
Chugai Pharma JPY 36.93B 9.04B 2025-12
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
DBV Technologies USD 3.63M 3.18M 2025-09
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Glaxosmithkline GBP 2.91B 817.89M 2025-09
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 86.56M 4.04M 2025-09
Karyopharm Therapeutics USD 27.19M 442K 2024-12
Neurocrine Biosciences USD 291.6M 5.3M 2025-09
Novavax USD 66.95M 34.05M 2024-09
PTC Therapeutics USD 84.05M 1.22M 2025-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
Ultragenyx Pharmaceutical USD 86.62M 26K 2025-09
Vertex Pharmaceuticals USD 445.1M 20.5M 2025-09


BioCryst Pharmaceuticals Vertriebs- Und Verwaltungskosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.